Background. The objective of this study was to ascertain patient preferences for treatment of hepatitis C virus (HCV). Methods. The authors recruited consecutive patients eligible for treatment of HCV and used adaptive conjoint analysis (ACA), a hybrid approach of conjoint analysis that uses both self-explicated ratings and pairwise comparisons, to elicit preferences for pegylatedinterferon and ribavirin. They examined the association between patient characteristics and treatment preferences using the Mann-Whitney U test and w 2 statistic for continuous and categorical variables, respectively, and subsequently calculated adjusted odds ratios and 95% confidence intervals using logistic regression. Results. A total of 140 subjects completed the ACA task. The mean (+SD) age of the sample was 51+8 y; 85% were male, and 59% were white. When described as being associated with mild side effects, 67% (n = 94) of subjects preferred
Background. The objective of this study was to ascertain patient preferences for treatment of hepatitis C virus (HCV). Methods. The authors recruited consecutive patients eligible for treatment of HCV and used adaptive conjoint analysis (ACA), a hybrid approach of conjoint analysis that uses both self-explicated ratings and pairwise comparisons, to elicit preferences for pegylatedinterferon and ribavirin. They examined the association between patient characteristics and treatment preferences using the Mann-Whitney U test and w 2 statistic for continuous and categorical variables, respectively, and subsequently calculated adjusted odds ratios and 95% confidence intervals using logistic regression. Results. A total of 140 subjects completed the ACA task. The mean (+SD) age of the sample was 51+8 y; 85% were male, and 59% were white. When described as being associated with mild side effects, 67% (n = 94) of subjects preferred treatment for HCV. The percentage of subjects preferring therapy decreased to 51% (n = 72) when it was described as being associated with severe side effects. Preferences for treatment of HCV were stronger among subjects with a higher perceived risk of developing cirrhosis, more severe underlying liver disease, and worse HCV-related quality of life. Subjects having more severe disease placed greater weight on the importance of expected benefits and less on the risk of toxicity compared with those with mild or no fibrosis. Conclusions. Whether to choose treatment for HCV is a difficult decision for many patients. Treatment is usually recommended for those with moderate to severe liver disease, and these results demonstrate that most patients' preferences are concordant with this practice. Key words: hepatitis C; decision making; pegylated-interferon; ribavirin. (Med Decis Making 2010;30: [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] C hronic hepatitis C virus (HCV) infection is a major health care burden among Americans, particularly in American veterans. At present, it is the most common indication for liver transplantation in the country, accounting for 30% of transplant cases. 1 It is estimated that the seroprevalence of HCV is 1.8% in the general US population, 2 whereas it is 5.4% in a population of Veterans Affairs medical center users. 3 Although definitive data on long-term outcomes are lacking, studies have shown that sustained virological response (SVR) to treatment appears to be associated with a decreased rate of disease progression and improved survival. [4] [5] [6] [7] [8] Over the past decade, treatment of HCV has evolved favorably from a 5% to 10% SVR with 24 wk of interferon monotherapy, to the current 54% to 56% SVR with 48 wk of pegylated-interferon and ribavirin. 9, 10 The efficacy of antiviral therapy, however, has to be considered in the context of the natural history of HCV. Cirrhosis develops in 7% to 20% of patients, whereas liver-related mortality occurs in up to 3.7% of patients over an average follow-up of 16 y. [11] [12] [13] [14] Moreover, chronic HCV does not progress at a uniform rate in all patients. Therefore, although antiviral therapy is effective at reducing progression to cirrhosis and the development of complications related to cirrhosis, at the individual patient level, many patients may not derive any benefit from treatment. Furthermore, the medications that are currently available can cause potentially serious adverse effects.
Given the tradeoffs involving uncertain benefits and risk of toxicity, treatment for HCV should incorporate patients' treatment preferences. It is especially important to consider patients' values in this decision because their valuations of outcomes in HCV differ from those of physicians. In contrast to previous studies that have examined patients' values for multiattribute health states 15, 16 and their preferences for the timing of general health states related to HCV, 17 the objective of this study was to ascertain patients' treatment preferences for HCV in clinical practice at the actual time of decision making.
METHODS

Subjects
The study was conducted at 2 sites: the VA Connecticut Healthcare System Liver Clinic and the Yale University Liver Clinic. The Hepatitis C Resource Center at VA Connecticut is an innovative multidisciplinary model of care that specifically targets veterans with chronic HCV who have psychiatric comorbidities, including mental illness and alcohol or drug abuse. Patients referred to this clinic undergo a pretreatment intervention that includes, in addition to medical evaluation, a standardized group education class and psychiatric evaluation. Both the VA and university clinics are attended by the same hepatologists.
Because the purpose of this study was to describe patient preferences for treatment at the actual time of decision making, we recruited consecutive patients eligible for treatment of HCV. Eligibility criteria included chronic HCV, no prior treatment for HCV, known genotype, and liver biopsy within the preceding 2 y or clinical evidence of cirrhosis. Inclusion criteria were based on the recommendations of the National Institute of Diabetes and Digestive and Kidney Diseases, which state that patients with chronic HCV and evidence of chronic hepatitis on liver biopsy, and with no contraindications, should be offered therapy with the combination of peginterferon and ribavirin regardless of the presence of symptoms or genotype. 18 Subjects were recruited by their treating physician, advanced practice registered nurse (APRN), or the research nurse at their liver biopsy appointments. Eligible patients signed informed consent either at their biopsy visit or when they arrived for their study visit, which was held on the same day as their follow-up appointment with their hepatologist. Subjects who did not have a scheduled liver biopsy were invited to participate by clinic staff and consented by the research nurse on the day of their study visit.
Data Collection
Data were collected on the day subjects were scheduled to talk to their physician about treatment for HCV. Subjects were asked to come in 90 min before their appointment to participate in the study. Because expected treatment benefits vary depending on the extent of underlying liver disease, all patients were informed of their biopsy results by their physician or APRN before completing the surveys.
All data were collected in a private room with the help of the research nurse. Before performing the preference task, subjects completed a questionnaire to ascertain sociodemographic characteristics, alcohol and drug use, [19] [20] [21] social support, 22 overall health status, 23 HCV-related quality of life, 24 mental illness, trust in physician, 25 and decisional conflict. 26 Decisional conflict was measured using the Decisional Conflict Scale, 26 a well-validated instrument composed of 16 items in which scores can range from 0 (representing no decisional conflict) to 100 (representing extremely high decisional conflict). For patients without cirrhosis, we also ascertained subjects' perceived risk of developing cirrhosis without treatment on a numeric rating scale ranging from 0 to 100. 27 We elicited treatment preferences using adaptive conjoint analysis (ACA; Sawtooth Software 1 , Sequim, WA). Conjoint analysis is a well-validated tool originally developed to understand consumer preferences and predict market shares of innovative products [28] [29] [30] and now has been widely used to elicit preferences for health care. 31, 32 Conjoint analysis is a decompositional technique that is based on the premise that respondents' preferences can be calculated based on the value that they attach to the specific attributes of the products under consideration. This method assumes a ''composition rule,'' which states that every attribute level has some value and that the value of the product is equal to the sum of its part values. 33, 34 We composed an ACA questionnaire to elicit preferences for treatment of HCV with pegylatedinterferon and ribavirin. The survey included 5 treatment characteristics or attributes (benefit, need to monitor blood tests, and risks of flulike illness, fatigue, and depression) and a total of 13 levels, which are detailed in Appendix A. To ensure that subjects were presented with individualized estimates of potential benefits, we created 8 versions of the ACA questionnaire for patients with varying degrees of fibrosis on biopsy (none, mild, moderate, or cirrhosis) and genotype (1 or 2; detailed in Appendix B). Rates of SVR and outcomes (progression to cirrhosis for patients without cirrhosis and development of liver failure or cancer for patients with cirrhosis) were obtained from the literature. 9, 10, 35 We also used patient testimonials obtained from preparatory focus groups to describe potential adverse events (Appendix C) and pictographs to facilitate risk communication.
ACA is a hybrid approach of conjoint analysis in that it uses both self-explicated ratings and pairwise comparisons to predict preferences. As such, participants first rated the importance of the difference between best and worst estimates of each characteristic ( Figure 1 ) and subsequently completed a series of paired comparisons ( Figure 2) . A 9-point scale was used in the pairs section so that finer differences in strength of preference could be derived. 36 The design of the conjoint survey is determined by the ACA software. ACA ensures that the choices presented in each pair always have different levels of the same attributes and are displayed at random on either the right or left screen. The minimum number of recommended pairs presented by ACA is determined by a built-in formula, 3 × (N -n -1) -N, where N is the total number of levels across all attributes and n is the total number of attributes. We included 10 pairs, 2 more than recommended by the formula [3 × (13 -5 -1) -13 = 8 pairs].
ACA constructs pairs by examining all the possible ways the levels can be combined and then chooses pairs of options for which it expects respondents to be indifferent (based on previous responses). Each question involves choosing 1 option from a pair in which one is superior in one attribute and the opposing option is superior in the other. If one option is clearly superior to the other based on ACA's initial estimate of utilities, no additional information is learned. The program uses the information obtained from each paired comparison to update the estimates of each respondent's utilities and to select the next pair of options. The choice of which levels are presented are based on the 3 additional premises: 1) that the design should be as balanced as possible, 2) that observations should be spread as evenly as possible over all levels, and 3) that the columns of the design matrix should be as orthogonal as possible. Further details describing how pairs are constructed are available. 37 
ACA Output
Answers to the survey questions are used by the software to calculate utilities or part-worths for each level of each attribute using ordinary least squares regression. The precise methods for how the software computes part-worths for the rating and pairs sections have been published. 37 In brief, conjoint models are regression models. The coefficients from the model are the utilities. In ACA, regression models are constructed for each individual respondent. The models are constructed based on an individual respondent's ratings of the question included in the survey. This approach assumes that the respondent's ratings reveal some information about how he or she values the specific characteristics included in the survey. Characteristics that are rated higher are presumed to be of greater value or utility. A respondent's utility is therefore a measure of his or her relative preference for each level of each attribute. Utilities are calculated using a least squares updating algorithm. The final utility estimates reflect true least squares. 37 Market simulators are then used to convert the raw utilities into preferences for options specified by the investigator based on the assumption that subjects prefer the option with the highest utility. Because we found that patients differed substantially in how they reported being affected by the side How much does this difference influence your decision about treatment? NO increased risk of depression/irritability. effects in preparatory focus groups, 38 we examined treatment preferences under 2 conditions: when treatment was associated with severe side effects and when treatment was associated with mild side effects. We predicted preferences using the randomized 1st-choice model in which utilities are summed across the levels corresponding to each option and then exponentiated and rescaled so that they sum to 100. This model accounts for the error in the point estimates of the part-worths during simulations and is recommended for analysis of individual-level utilities. 39 Details related to this model have been previously published. 39 Subjects with shares of preferences greater than 50% were classified as preferring therapy.
To determine the relative impact of each attribute included in the ACA survey on subjects' preferences, we divided the range of utilities for each characteristic by the sum of ranges and multiplied by 100. The relative importances are proportions and sum to 100. 37 
Statistical Analyses
Patient characteristics were entered into SAS computer files (SAS Software, version 9.1; SAS Institute, Inc., Cary, NC). Preference data derived from ACA were imported into and merged with the patient characteristics data set. We examined the association between patient characteristics and treatment preference using the Mann-Whitney U test and w 2 statistic for continuous and categorical variables, respectively. We subsequently calculated adjusted odds ratios and 95% confidence intervals using logistic regression. All variables found to be significant at P ≤ 0.05 in bivariate analyses were entered into the model. We used the postestimation Wald test to assess the individual contribution of each variable. Given possible differences between the VA and university settings, we also performed exploratory subgroup analyses by site.
RESULTS
Patient Characteristics
Of 212 eligible subjects, 178 agreed to participate and 140 performed the ACA task; all completed the entire survey. The computer task was not performed in 38 eligible patients for the following reasons: 21 patients canceled or did not come to their appointment, 6 patients did not have the time to complete the task, 8 could not participate because of a scheduling error, and the computer malfunctioned on 3 occasions. The mean (+SD) age of the sample was 51 + 8 y, 85% were male, 59% were white, and 30% were black. Further details regarding subjects' characteristics are provided in Table 1 .
Treatment Preferences
Sixty-seven percent (n = 94) of subjects preferred treatment for HCV if associated with mild side effects. The percentage of subjects preferring therapy decreased to 51% (n = 72) when it was described as being associated with severe side effects.
The associations of subjects' characteristics and preference for treatment described as being associated with severe side effects are reported in Tables 2  and 3 . In unadjusted analyses, we found that women, as well as subjects with a higher perceived risk of developing cirrhosis, more severe liver disease, genotype 2, and worse HCV-related quality of life, were more likely to prefer treatment. Those with greater decisional conflict were less likely to prefer treatment. In bivariate analyses, associations with preference for treatment described as having mild side effects were the same as those reported in Tables 2 and 3 except for genotype 1 versus 2 (66% v. 83%, P = 0.1) and gender (65% v. 81%, P = 0.1), which were not associated with preference and trust in physician, which was (57 v. 55 , P = 0.04]. Adjusted analyses are reported in Table 4 . We found no other relationships between the remaining demographic characteristics, the use of drugs or alcohol, current health status, or social support and treatment preference.
Given that we recruited patients from 2 distinct sites, we also performed exploratory subgroup analyses by site (Tables 5 and 6 ). In these analyses, patients reporting a history of mental illness were more likely to prefer treatment at the VA (60% v. 37%, P = 0.02) but less likely to prefer treatment at the university clinic (44% v. 71%, P = 0.07). In addition, the extent of underlying liver disease was a strong predictor of preference at the VA but not at the university clinic (Table 7) . At both sites, the majority of patients with either moderate or severe fibrosis preferred treatment. However, subjects at the university clinic with mild or no fibrosis were more likely to prefer treatment compared with those recruited from the VA (50% v. 24%, P = 0.08). 
Relative Impact of Treatment Characteristics
The relative impact of the treatment characteristics included in the survey on subjects' preferences is illustrated in Figure 3 . Overall, the likelihood of benefit was most important to subjects and the need for blood test monitoring least important. The risks of fatigue, depression, and flulike illness all had similar influences on subjects' preferences. Table 8 displays the impact of each characteristic by severity of liver disease. These results demonstrate significant associations between the severity of liver disease on biopsy and the relative impact of risk and benefits, with subjects having more severe disease placing greater weight on the importance of expected benefits and less weight on the risk of toxicity compared with those with mild or no fibrosis. This pattern was also observed in subgroup analyses by site.
DISCUSSION
In summary, we found significant variability in preferences for treatment of HCV among patients with mild to moderate disease. In contrast, almost all patients with more severe fibrosis had a strong preference for treatment. To the best of our knowledge, this is the 1st study to examine treatment preferences for HCV using individualized outcome data in routine clinical practice at the time of decision making. Our results mirror current recommendations from the National Institutes of Health Consensus Development Conference Panel, 40 as well as guidelines from the American Gastroenterological Association 41 and American Association for the Study of Liver Diseases, 42 which recommend treatment for all eligible patients with moderate to severe liver disease and individualized treatment planning based on patient preferences for those with milder degrees of inflammation on liver biopsy. Other studies have also demonstrated significant variability in treatment preferences. Falck-Ytter and others 43 described lower rates of refusal but included populations with patients who were not eligible for treatment. Khokhar and others 44 found that 41% of eligible patients refused or deferred treatment. However, the impact of underlying liver disease on preferences was not evaluated in this article. The most common reason for deferral in the study by Khokhar and others was the lack of symptoms experienced by patients and their concerns related to side effects. 44 In this study, we found similar concerns related to toxicity and further noted that the impact of toxicity varies with the severity of underlying liver disease. However, the finding that the extent of underlying liver disease is a stronger predictor of preference than HCV-related quality of life suggests that it is patients' worry related to their prognosis, and not symptom burden, that is the primary determinant of decision making. We also found that subjects with greater decisional conflict were more likely to refuse treatment. This finding is consistent with studies demonstrating that people are more likely to opt out or defer decision making when faced with a difficult choice task 45 and emphasize the need to provide patients with adequate decisional support.
We did not find any effect of age or race on patient preferences. These results suggest that reasons outside of patient preferences account for the lower frequency of treatment observed among women, older adults, and nonwhite patients found in previous studies. 46, 47 Exploratory subgroup analyses by site revealed several interesting findings. First, treatment preferences among subjects recruited from the VA were strongly related to severity of underlying liver disease and perceived risk of cirrhosis, whereas this association was much weaker among subjects cared for at the university clinic. This difference may be due to the formal education classes that most veterans with HCV attend. An alternative explanation may be that subjects outside of the VA may have stronger opinions regarding therapy before consulting with a specialist compared with the veteran population. In addition, we found that subjects who reported having a history of mental illness were more likely to prefer therapy at the VA and less likely to prefer therapy in the university clinic. This difference is almost certainly due to the specialized care afforded to patients with comorbidities at the Hepatitis C Resource Centers developed within the VA health care system. The strengths of this study lie in the methods used to evaluate preferences as well as the successful recruitment of a substantial number of patients at the time of decision making. There are also several limitations of this study. Although there are no clear methods for determining sample size in ACA studies, the total population recruited for this study is in keeping with previous analyses using similar methods. 28, 48, 49 We present the subgroup analyses because of probable differences between universitybased and VA populations; however, it is important to note that only a small number of patients were able to be recruited from the university-based clinic.
The subgroup results should be viewed as hypotheses generating only.
Patients with HCV cover diverse sociodemographic groups, and participants recruited for this study may not be representative of other communitybased samples. In addition, because we were interested in describing patient preferences at the actual time of decision making, only patients eligible for treatment were recruited. Preference data from the general population would be better suited to inform public health and/or policy decisions. Lastly, the relative impact of the medication characteristics on patients' preferences refer only to the attributes (and the ranges of their respective levels) included in the ACA survey and do not account for other concerns that may be important determinants of patients' decision making.
Treatment planning may be relatively straightforward for patients with significant fibrosis given the concordance between guideline recommendations and patients' strong preference for treatment. Decision support is most important for patients with milder disease in whom there is substantial variability in treatment preferences due to the differences in how patients value the potential risks and uncertain benefits associated with therapy.
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We very much appreciate the support of Carol Eggers, APRN, and Martha Shea, RN, who greatly facilitated recruitment for this study. I used to look forward to getting home and taking a nap. Sometimes you get up in the morning and you feel like you are hung over. It's a chore to go to the grocery store. It's a chore to get my laundry done.
2. Severe: You may feel extremely tired a lot of the time, and it interferes a lot with your activities. You may have to take many days off from work, or not be able to take care of your children at times.
I was tired. I couldn't deal with anything. When I'd go to work I just wanted to go to sleep. But I made it through lunch. I'd sleep for an hour. I wouldn't bother eating, because I'd just fall asleep. I would get home and sometimes I couldn't even get in the shower and I would just take my clothes off and on the bed, boom, and I'd be out.
Depression/Irritability 1. Mild: You may feel very sad or irritable more often than usual, but it does not interfere with your important activities, such as working. You may have some trouble getting along with family, friends, and coworkers.
The emotional part is being on a roller coaster. It was down, up, down, up. I just wanted to be left alone. I was snapping. You know my fuse was definitely shortened. I'd say all of the things you are only meant to be thinking.
2. Severe: You may feel very depressed and irritable and be worried about losing your temper. You may feel like you want to isolate yourself from others. You may have a lot of trouble getting along with your family, friends, and coworkers. You will need to see a doctor or therapist to help you.
I cried, and cried and cried. Uncontrollable tears for 2 months. My mood swings were wild. I was in a dark place. I just felt awful. It was like an uncontrollable sense of anger. I have children and they would be in absolute avoidance of me. If someone pushed my button wrong, I exploded. I'm surprised I have any friends left.
Management of Side Effects
The experience of this clinic staff is that these side effects can be managed in most people. Often the side effects are worse in the first few months.
• For flu symptoms, Tylenol and ''drink a lot of water'' are the main things recommended. • For fatigue, there is no treatment, but the clinic can help you find ways to manage your responsibilities. • For depression or irritability, you can be given medications and be followed by psychiatric staff.
All of these things may be helpful to many people but do not help everyone.
